Skip to main content
STAR COMBO PHARMA LIMITED logo

STAR COMBO PHARMA LIMITED — Investor Relations & Filings

Ticker · S66 ISIN · AU0000004798 ASX Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2020-10-22 Governance Information
Country AU Australia
Listing ASX S66

About STAR COMBO PHARMA LIMITED

https://www.starcombo.com.au

Star Combo Pharma Limited specializes in the development, manufacturing, and distribution of vitamins, dietary supplements, and skincare products. The organization operates Therapeutic Goods Administration (TGA) licensed facilities, offering comprehensive Original Equipment Manufacturing (OEM) and Original Design Manufacturing (ODM) services. Its product portfolio encompasses a wide range of health and beauty solutions marketed under proprietary brands, including Costar, Living Healthy, Amax, and J&K. The company focuses on delivering premium health products to diverse markets, leveraging technical expertise in formulation and large-scale production. By maintaining rigorous quality control standards and providing end-to-end manufacturing solutions, the entity serves as a strategic partner for businesses seeking customized health and wellness products.

Recent filings

Filing Released Lang Actions
S66 App 4G and Corporate Governance Statement 21 pages 364.9KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures required to be lodged with the ASX alongside the annual report. The content is a detailed key to disclosures against the ASX Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2020. It includes explanations of compliance or non-compliance with governance recommendations, references to the corporate governance statement, and URLs where the full statement can be found. The document is not the annual report itself but a governance disclosure document required by ASX listing rules. It is a governance-related filing focused on corporate governance practices and compliance with governance principles, not financial results or management changes. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-10-22 English
Appointment of Auditor 1 page 63.2KB
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the appointment of a new auditor for Star Combo Pharma Ltd. It references compliance with Listing Rule 3.16.3 and the Corporations Act 2001, and mentions that a resolution will be proposed at the upcoming Annual General Meeting to confirm the auditor's appointment. The document does not contain any financial statements, audit results, or detailed audit reports. It is a regulatory announcement about a change in auditor rather than the audit report itself or an annual report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-10-12 English
S66 Investor Roadshow Presentation September 2020 20 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is titled 'INVESTOR ROADSHOW PRESENTATION' and contains detailed information about the company's financial results for FY20, business operations, growth strategy, investment plans, manufacturing facilities, and market positioning. It includes revenue figures, investment capital strategy, expansion plans, and market analysis. The content is structured as a presentation aimed at investors, focusing on financials, strategy, and market position rather than a formal regulatory filing or report. There is no indication that this is an official annual or interim report, audit report, or earnings release. The document is clearly a presentation prepared for investor communication purposes, consistent with the definition of an Investor Presentation (IP).
2020-09-07 English
$11m Transformational Investment 1 page 71.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 1 September 2020 from Star Combo Pharma Ltd. It details a capital investment of $11 million for the acquisition of new production lines and upgrading manufacturing facilities. The content focuses on the company's expansion plans and funding source (cash reserves). There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is an announcement about a financing and capital expenditure update rather than a full financial report or earnings release. It fits the description of a Capital/Financing Update (CAP) as it informs investors about a significant investment and capital deployment strategy.
2020-08-31 English
Preliminary Final Report 67 pages 2.5MB
Annual Report Classification · 98% confidence The document is titled 'APPENDIX 4E PRELIMINARY FINAL REPORT FOR THE YEAR ENDED 30 JUNE 2020' and includes detailed financial data for the full fiscal year ending June 30, 2020. It contains a Directors' Report, Remuneration Report, Auditor's Independence Declaration, Financial Statements, Directors' Declaration, and Independent Auditor's Report. The presence of comprehensive financial statements and detailed management discussion indicates this is a full annual report. The document length is substantial (15,000 characters), and it is not merely an announcement or a certification. The content matches the characteristics of an Annual Report (10-K equivalent) filing, covering company activity and full financial performance for the year.
2020-08-25 English
FY 2020 Results Commentary 4 pages 139.5KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 26 August 2020, titled 'Financial Year 2020 Results Commentary'. It provides a detailed commentary on the full year financial results for FY20 ending 30 June 2020, including revenue figures, EBITDA, operational updates, strategic initiatives, and outlook. The document contains substantive financial data and analysis, such as revenue growth, loss reduction, EBITDA figures, and business segment contributions. It is not merely a brief earnings highlight or a short announcement of results but a comprehensive financial year results commentary. It is not a full Annual Report (10-K) but fits the profile of an Interim/Quarterly Report (IR) as it covers a financial period shorter than a full fiscal year report and contains detailed financial data and operational commentary. The document is longer than 5,000 characters and contains actual financial statements and analysis, so it is not a report publication announcement or regulatory filing. Therefore, the best classification is Interim / Quarterly Report (IR).
2020-08-25 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.